
NYSE:STZ
This summary was created by AI, based on 2 opinions in the last 12 months.
Constellation Brands Inc (STZ-N) is set to report earnings insights that highlight mixed perspectives from analysts. One expert expresses optimism, showcasing confidence in the newly appointed CEO and anticipating a positive shift in beer and cocktail sales. Conversely, another expert paints a more negative picture, noting that the broader alcohol industry, including Constellation, has struggled recently, facing challenges such as decreased sales driven by ICE raids in key shopping areas. This year, the stock has experienced a significant decline of 36%, with its current price-to-earnings ratio at a notably low 12x. While some view this low valuation as attractive, it is deemed justified due to ongoing weak sales and the emergence of competition from GLP-1 drugs. Overall, while there are signs of potential recovery, significant headwinds linger for Constellation Brands.
Their focus is their internal liquor brands, whose sales have been flat. They invested in cannabis (Canopy) as a way to grow, but is stalled. We'll see about the long-term. Invest elsewhere in consumer staples.
The push out of a senior executive, Bruce Linton, at WEED-T is a good signal for the company he thinks. There was not damage done by the Exec and he has done well personally by the agreement and is off the Board as well. This gives the Exec a great opportunity to sell his shares at a great value. The company has a $40 billion market cap. Constellation Brands had to take a charge against their $5 billion investment. Right now, Norman believes this is not an investable space yet -- the real leaders have not yet emerged. He expects further shake-outs in the space to come. There is no real brand recognition today.
One of the world’s largest beverage makers. Is a high risk stock. Probably has about as good a chart you can have. Just seems to be in a sidewise consolidation pattern right now. With respect to their Canopy investment, the marijuana space has dropped significantly and this will impact the share price of Constellation.
It is interesting that they are investing into Canopy. He thinks it is more like a hedge for them. In the context it is a cheap hedge. This shouldn’t be the basis to invest in the stock. The marijuana space is nascent. He wouldn’t analyze the company with that component. He wouldn’t invest in this stock.
He owned this before they bought in Canopy. They own Corona and other Mexican brands, plus wine. The beers have been growing very well. STZ has one of the best growth rates in a sluggish sector. He isn't a cannabis bull, but he sees upside in this space. (1.4% dividend, Analysts' price target: $242.00)